Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Linggui Zhulian Decoction (LGZLD) is a modified Traditional Chinese Medicine (TCM) formula developed by the Department of Endocrinology at the Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine. It is specifically designed to treat obesity and insulin resistance. The formula is a modification of the classic Linggui Zhugan Decoction, replacing Glycyrrhiza uralensis with Coptis chinensis to better address the damp-heat and phlegm-dampness patterns often associated with metabolic disorders. LGZLD contains four primary herbal components: Poria cocos, Cinnamomum cassia, Atractylodes macrocephala, and Coptis chinensis. Its mechanism of action involves the modulation of gut microbiota, reduction of systemic inflammation (lowering TNF-alpha and IL-6 levels), and enhancement of insulin signaling via the PI3K/Akt pathway. Clinical and preclinical studies have demonstrated its efficacy in improving body mass index (BMI), waist circumference, and homeostatic model assessment for insulin resistance (HOMA-IR) in patients with metabolic syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on linggui zhulian decoction.